6 days ago
- Inflammatory bowel disease (IBD) involves gut immune dysregulation, barrier dysfunction, and microbial imbalance, with bacterial dysbiosis well-studied.
- The gut virome and mycobiome are underexplored due to technical challenges like sequencing bias and incomplete databases.
- Fungal and viral dysbiosis are linked to IBD, including Candida overgrowth, loss of Saccharomyces, and expansion of specific phages and viruses.
- These alterations impact barrier integrity, immune signaling, and cross-kingdom interactions, amplifying inflammation.
- The virome and mycobiome offer therapeutic targets, such as probiotics, phage therapy, and fecal virome or microbiota transplantation.
- Research highlights the need for biomarker discovery and multikingdom microbiota-directed therapies in IBD.